PFC
AMLX icon

Phocas Financial Corp’s Amylyx Pharmaceuticals AMLX Stock Holding History

Phocas Financial Corp’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$1.27M Buy
+86,073
New +$1.32M 0.17% 125

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Phocas Financial Corp's AMLX Position: Q4 2023 in Review

Phocas Financial Corp opened a new position in Amylyx Pharmaceuticals (AMLX) in Q4 2023: 86,073 shares worth $1.27M. The stake represents 0.17% of the portfolio and ranks #125 among its holdings.

178 funds tracked by Wall St. Rank hold AMLX as of Q4 2023.

  • Phocas Financial Corp held 86,073 shares of Amylyx Pharmaceuticals worth $1.27M as of Q4 2023.
  • Amylyx Pharmaceuticals was a new Phocas Financial Corp position in Q4 2023.
  • Amylyx Pharmaceuticals made up 0.17% of Phocas Financial Corp's portfolio in Q4 2023, its #125 holding.
  • 178 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2023.

Based on Phocas Financial Corp's 13F filing for Q4 2023, filed 30 Jan 2024.